Plain-English translation of NCT07073638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called that you would inhale three times a day. The study has two stages: in the first stage, patients receive alone; in the second stage, patients receive combined with standard tuberculosis medications taken by mouth. Researchers want to understand whether this medication is safe, well-tolerated, and effective at fighting the tuberculosis bacteria.
Current tuberculosis treatments take a long time and can have side effects. This trial exists to see whether an inhaled medication might work better, faster, or with fewer side effects than existing options.
You likely qualify if…
You likely don't qualify if…
In Stage 1, you would come to a single research center and inhale 6 milliliters of the medication three times each day using a nebulizer (a machine that turns liquid medicine into a mist you breathe in). In Stage 2, you would inhale the same medication three times daily AND take standard tuberculosis pills once a day by mouth. The trial involves screening tests to check your lung function and ability to produce sputum, and ongoing visits to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
South Africa
Phase
Testing effectiveness
Sponsor
Thirty Respiratory Limited
Enrollment target
~24 participants
Started
October 2025
Primary completion
September 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in January 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.